Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176488 · ClinicalTrials.gov registry record · Phase 2
Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
A Phase 2 study, sponsored by University of Medicine and Dentistry of New Jersey.
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00176488 is a Phase 2 study that was terminated before completion, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 31 participants.
The verdict
NCT00176488, a Phase 2 study, was terminated before completion, sponsored by University of Medicine and Dentistry of New Jersey.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as epirubicin and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving epirubicin together with vinorelbine may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving epirubicin together with vinorelbine works in treating patients with stage II, stage III, or stage IV breast cancer.
Interventions
- DRUG vinorelbine
- DRUG epirubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2003-06 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176488
The ClinicalTrials.gov registry entry for NCT00176488 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Medicine and Dentistry of New Jersey, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which vinorelbine is the first listed.
NCT00176488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00176488 about?
NCT00176488 is a clinical study titled "Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as epirubicin and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving epirubicin together with vinorelbine may kill more tumor cells. PURPOSE: This phase II trial is ...
What is the current status of trial NCT00176488?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2003-06. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00176488?
The interventions under investigation include: vinorelbine (DRUG), epirubicin (DRUG).
Who is sponsoring clinical trial NCT00176488?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.